Market Intelligence, Clinical Progress, and High-Purity Reagents for Type 2 Inflammation and Allergic Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-4 Recombinant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed (native glycosylation). | View IL-4 Products |
| Receptor | IL-4Rα ECD-Fc Fusion Protein. Type I/II receptor component. Native glycosylation preserved. | View IL-4Rα Products |
| Partner Cytokine | IL-13 Recombinant Protein. Shared signaling pathway component; essential for cross-reactivity testing. | View IL-13 Products |
| Gene Delivery | IL-4 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. Puromycin selection. | View IL-4 Products |
| Benchmark Ab | Anti-IL-4Rα (Dupilumab biosimilar). Sequence-matched positive control; blocks IL-4 and IL-13 signaling. | View IL-4Rα Products |
| Validator | IL-4 siRNA Set. For knockdown verification and specificity controls in cell-based models. | View IL-4 Products |
| Related Target | IL-13. Synergistic Th2 cytokine sharing IL-4Rα/IL-13Rα1 signaling axis. | View IL-13 Products |
| Related Target | IL-4Rα. Common receptor subunit for IL-4 and IL-13; required for receptor occupancy assays. | View IL-4Rα Products |
| Related Target | IL-5. Parallel Type 2 cytokine pathway critical for eosinophil biology. | View IL-5 Products |
| Related Target | IL-13Rα1. Type II receptor subunit; determines tissue-specific signaling. | View IL-13Rα1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species translation (Cyno/Mouse eval) | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and verified Theoretical MW. |
| Receptor binding kinetics (SPR/BLI) | Endotoxin controlled (<1EU/ug) and natively glycosylated in HEK293 for accurate structural fidelity. |
| Dual pathway blockade (IL-4 & IL-13) | Human/Mouse/Cyno IL-4Rα ortholog proteins available; mass spec verified. |
| Type I vs Type II receptor selectivity | Homolog panel: IL-4Rα, IL-13Rα1, γc chain. Strict sequence verification for epitope mapping. |
| Lack of positive controls | Clinical benchmark antibodies (Dupilumab biosimilar) included for assay calibration. |
| False positives in signaling assays | Validated siRNA included for STAT6 phosphorylation specificity checks. |
| Clinical benchmarking | Anti-IL-4Rα biosimilar (Dupilumab sequence) for assay standardization. |
Live IL-4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-4/IL-13 pathway therapeutics is intensifying, with major players shifting focus from traditional broad immunosuppressants to precision cytokine blockade. Dupilumab (anti-IL-4Rα) has established proof-of-concept across multiple Type 2 inflammatory indications (atopic dermatitis, asthma, eosinophilic esophagitis), creating a template for next-generation modulators. As first-generation therapies expand into pediatric populations and fibrotic diseases, the next wave of R&D is targeting receptor subtype selectivity, tissue-specific delivery mechanisms, and extended half-life. Emerging trends include bispecific antibodies (IL-4/IL-13), inhaled biologics for COPD, and combination regimens with IL-33/TSLP inhibitors to address non-responders.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-IL-4Rα mAb | Regeneron/Sanofi, Roche | Atopic Dermatitis, Asthma, CRSwNP | Dual cytokine neutralization assay (Need IL-4 + IL-13 proteins) |
| Anti-IL-4 mAb | Pascolizumab (legacy), Biotech startups | Severe Asthma | Type I receptor specific binding (Need γc chain co-expression) |
| IL-4 Mutein | Molecular engineering firms | Immunotherapy modulation | Receptor binding affinity panels (Mutant vs WT proteins) |
| IL-13/IL-4 Bispecific | AstraZeneca, Pipeline candidates | Fibrosis, Eosinophilic Esophagitis | Heterodimer validation (Need cross-reactive Abs and dual antigens) |
| Inhaled Biologics | AstraZeneca, Pieris | COPD, Asthma | Stability testing (Need endotoxin-controlled, stable proteins) |
| Small Molecule (JAK/STAT) | Pfizer, AbbVie | Dermatology, Autoimmune | Pathway screening (Need native cytokines for stimulation) |